Topic

MSCA-IF-2018

MSCA-IF-2018

Programme: H2020

1375 projects · €277,224,487 total EU contribution (project-level) · 562 participating organizations · 41 countries with participants

Total EU funding

Sum of EC max contribution fields for distinct projects in this topic.

€277,224,487

Countries active

Participant organizations by country (headquarters in CORDIS).

  • UK (68)
  • Spain (64)
  • US (59)
  • Germany (57)
  • France (52)
  • Italy (40)
  • Netherlands (27)
  • CH (19)
  • AT (18)
  • CA (15)
  • PT (13)
  • BE (12)
  • IE (12)
  • SE (12)
  • AU (11)
  • DK (11)
  • TR (9)
  • FI (8)
  • NO (8)
  • CZ (6)
  • EL (6)
  • IL (5)
  • CY (3)
  • NZ (3)
  • SI (3)
  • BR (2)
  • EE (2)
  • JP (2)
  • MX (2)
  • PL (2)
  • AR (1)
  • DZ (1)
  • HR (1)
  • HU (1)
  • KR (1)
  • LU (1)
  • RO (1)
  • RS (1)
  • SG (1)
  • VA (1)

Open calls

From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.

No open or forthcoming calls linked to this topic in the database yet.

Top organizations

By number of distinct projects in this topic.

Projects

Page 23 of 138

ProjectEU contribution

Novel Matrix Stiffness-regulated Genes in Lymphangiogenesis and Angiogenesis

STRomA · 840189

€162,806
Details

Maintenance and relapse in long-term desistance from crime and recovery from addiction

SLIPPED · 833630

€224,934
Details

Deconstructing the past: Modelling the locomotion of Miocene hominoids through computational techniques

DeMol · 837966

€212,934
Details

Local-global principles and zero-cycles

LocalGlobal0Cycles · 840684

€174,167
Details

Neural mechanisms of crossmodal activity in blind and sighted individuals

THE CROSSMODAL BRAIN · 840670

€162,806
Details

Non-Archimedean limits of differential forms, Gromov-Hausdorff limits and essential skeleta

nalimdif · 843100

€166,320
Details

Pathogenetic pathways in age-related neurodegenerations as novel therapeutic targets for Parkinson’s disease

PARNANT · 844497

€183,473
Details

Harnessing the innate and adaptive immune system with targeted neoantigen based cancer vaccines

SPLITVAC · 845349

€172,932
Details

Dissecting the molecular pathogenesis of Legionella spp. in human lung models

OPTIMISE · 844197

€212,934
Details

Polymeric cyclodextrin-based nanoparticles for combination therapy of castrate-resistant prostate cancer

POLAR STAR · 843014

€171,473
Details